subscribeSubscribe
Sanofi Q1 profit slips on generic competition, forex effects

Sanofi Q1 profit slips on generic competition, forex effects
Ludwig Burger REUTERS
25 Apr 2024
Share Share
ASLAN`s Eblasakimab Positive Interim Atopic Dermatitis Data

ASLAN`s Eblasakimab Positive Interim Atopic Dermatitis Data
GLOBENEWSWIRE
22 Apr 2024
Share Share
Regeneron`s Dupixent (dupilumab) Receives Suppl Approval in the U.S.

Regeneron`s Dupixent (dupilumab) Receives Suppl Approval in the U.S.

FDA
12 Apr 2024
Share Share
Sanofi plans to launch 1 or 2 products in India every year

Sanofi plans to launch 1 or 2 products in India every year
Viswanath Pilla ECONOMICTIMES
01 Apr 2024
Share Share
Dupixent sBLA Accepted for FDA Priority Review for Treatment of COPD

Dupixent sBLA Accepted for FDA Priority Review for Treatment of COPD
GLOBENEWSWIRE
23 Feb 2024
Share Share
FDA grants priority review for Dupixent in COPD

FDA grants priority review for Dupixent in COPD
ENDPTS
22 Feb 2024
Share Share
After FDA says no on Dupixent for hives disorder, Japan says yes

After FDA says no on Dupixent for hives disorder, Japan says yes
FIERCE PHARMA
16 Feb 2024
Share Share
Japan first in the world to approve Dupixent® for CSU

Japan first in the world to approve Dupixent® for CSU
PRESS RELEASE
15 Feb 2024
Share Share
US FDA approves Dupixent to treat younger kids with esophageal condition

US FDA approves Dupixent to treat younger kids with esophageal condition
REUTERS
26 Jan 2024
Share Share
Regeneron`s Biologic Dupixent (dupilumab) Receives Approval in the U.S.

Regeneron`s Biologic Dupixent (dupilumab) Receives Approval in the U.S.
FDA
25 Jan 2024
Share Share